Antihyperglycemic and anti-inflammatory effects of fermented food paste in high-fat diet and streptozotocin-challenged mice

Noraisyah Zulkawi,¹ Kam Heng Ng,¹ Nur Rizi Zamberi,²,³ Swee Keong Yeap,¹ Dilan A Satharasinghe,¹ Sheau Wei Tan,² Wan Yong Ho,¹ Nur Yuhaisiza Abd Rashid,¹ Mohd Izwan Md Lazim,¹ Anisah Jamaluddin,¹ Noorjahan Banu Alitheen,¹,⁷ Kamariah Long¹

¹Technical Research – Product Development Department, Elken Global Sdn. Bhd, Kuala Lumpur, Malaysia; ²Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; ³Malaysian Agricultural Research and Development Institute (MARDI), Serdang, Selangor, Malaysia; ⁴China–ASEAN College of Marine Sciences, Xiamen University Malaysia, Sepang, Selangor, Malaysia; ⁵Department of Basic Veterinary Sciences, Faculty of Veterinary Medicine & Animal Science, University of Peradeniya, Peradeniya, Sri Lanka; ⁶School of Biomedical Sciences, The University of Nottingham Malaysia Campus, Semenyih, Selangor, Malaysia; ⁷Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Introduction
Diabetes is a global public health crisis contributed to by several factors including obesity, low physical activity, and intake of diet with excessive calories.¹ Type 2 diabetes is characterized by increased level of blood glucose due to insulin resistance.² Although several factors including obesity, low physical activity, genetics, and intake of diet with excessive calories contributed to the development of diabetes,¹ obesity caused by intake of Western high-fat diet (HFD) was one of the top risk factors.² To overcome the escalating diabetes health problem, several suggestions such as increasing physical activity and practicing healthy lifestyle or diet were proposed.³ It was hypothesized that traditional Asian diet including fermented food can help in preventing and delaying the progression of type 2 diabetes.⁴ Fermentation using lactic acid bacteria is a food processing method practiced since ancient time to improve flavor, aroma, and shelf life of fresh foods.⁵ Among the commonly used lactic acid bacteria, Lactobacillus...
plantarum has been reported as the safest way to preserve food. Recent studies have shown that fermentation also helps to remove anti-nutritional factors and enhances bioactive metabolites such as polyphenols and isoflavone, which contributed to the improvement of bio-activities such as antibacterial, anti-inflammatory, anti-allergy, antioxidant, antihypertensive, and tyrosinase inhibitory effects. In addition, fermented food was also reported with antidiabetic effect. For example, fermented soybean improved glucose control in diabetic mice by improved sensitivity of insulin and glucose metabolism. The antidiabetic effect of fermented food may be contributed by the polyphenolic acid and even the lactic acid bacteria that were used for fermentation.

Among the fermented food, fermented food paste (FFP) produced by fermenting fruits, vegetable, herbs, mushrooms, seaweed, and pulses using lactic acid bacteria is a convenient source of digestible nutrients in Japan. Xeniji™ is one of the commercial FFP that is available in Malaysia and Japan. A recent study has reported that FFP contained β-carotene, phytonadione, polyphenol, citric acid, and essential amino acids, which may have contributed to the antioxidant and immunostimulatory effect of 1 g/kg body weight (BW) of raw FFP (dissolved in distilled water) on healthy BALB/c mice in vivo. In addition, vitamin and polyphenols in fermented food were also correlated to its anti-inflammatory and inhibition of fat deposition effects. Presence of polyphenols particularly caffeoquinic acid and sakuranetin in 1 g/kg BW of raw FFP (dissolved in distilled water) was also correlated with its in vivo hepato-recovery effect on ethanol-induced liver damage of BALB/c mice. Although FFP contained essential amino acids, vitamins, and polyphenolic acids and fermented food has been recorded to have potential antidiabetic effect, benefit of this FFP in regulating hyperglycemia particularly on type 2 diabetes is still unclear. Mice fed with HFD and challenged with streptozotocin were described as suitable model to resemble type 2 diabetes. Thus, this model was used in this study to evaluate the anti-hyperglycemia and anti-inflammatory effect of FFP.

### Methods

#### Preparation of FFP

Commercially available FFP was provided by Elken Sdn Bhd, Malaysia. Preparation and ingredients of FFP were reported in the previous study. In brief, various food ingredients were batch fermented using commercial lactic acid bacteria (Table 1) for 3.5 years. Based on the previous study, FFP contained β-carotene, phytonadione, polyphenol, citric acid, and essential amino acids. FFP used in this study was evaluated and standardized based on total phenolic content (~5 mg GAE/g extract), citric acid (~30 mg/g extract), aspartic acid

<table>
<thead>
<tr>
<th>Table 1 Ingredients of FFP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Food ingredients</strong></td>
</tr>
<tr>
<td>Sugar</td>
</tr>
<tr>
<td>Fruits</td>
</tr>
<tr>
<td>Vegetables and wild herbs</td>
</tr>
<tr>
<td>Mushrooms</td>
</tr>
<tr>
<td>Seaweed</td>
</tr>
<tr>
<td>Pulses and cereals</td>
</tr>
<tr>
<td>Lactic acid bacteria species</td>
</tr>
</tbody>
</table>

(−30 mg/100 g extract), and β-carotene (−5 mg/g extract), which was similar to the our previous report.\textsuperscript{10} In this study, FFP was freshly prepared daily by dissolving in distilled water at the evaluated concentration prior to the supplementation.

**Animals and treatment**

Male mice (n=45, 6 weeks old) were purchased from animal house, Institute of Bioscience, Universiti Putra Malaysia (UPM). This study was approved by Institutional Animal Care and Use Committee, UPM (RO45/2016). All animal experiments were carried out in accordance with the Malaysia Animals Act 1953 (Revised 2006) under Malaysian Veterinary Council for animal experiments. The animals were acclimatized for 2 weeks before starting the experiment. All mice were housed under standard condition at 22°C, 12 hours of day/dark light cycles, humidity ~70%, and fed with distilled water and standard mouse pellets 702 (Gold Coin Holding, Selangor, Malaysia) ad libitum.

The mice were randomly divided into nine groups as stated below. Group 1 was the normal healthy mice that were fed with standard mouse pellets 702 (Gold Coin Holding,) throughout the experimental period. Mice from groups 2–5 were fed with HFD D12492 (Research Diet, Inc, New Brunswick, NJ, USA) ad libitum for 12 weeks. Major components of the standard diet and HFD are listed in Table 2.\textsuperscript{14} In addition, mice from groups 2–5 were injected with streptozotocin (35 mg/kg) (Sigma-Aldrich Co., St Louis, MO, USA) intraperitoneally on week 8.\textsuperscript{15} When the fasting glucose was >270 mg/dL at week 12, mice from groups 3–5 were orally fed with metformin (CCM Pharmaceuticals Sdn Bhd, Selangor, Malaysia) or FFP using oral gavage for 6 weeks as stated below. Previous studies\textsuperscript{16,12} have shown that 0.1 and 1.0 g/kg body weight (BW) of FFP enhanced the antioxidant effects in healthy and ethanol-induced liver damaged BALB/c mice. Thus, these concentrations were used in this study.

- Group 1, normal healthy (n=5): standard diet + normal saline buffer (Sigma-Aldrich Co.)
- Group 2, untreated diabetic (n=5): HFD + streptozotocin challenged + distilled water
- Group 3, metformin diabetic (n=5): HFD + streptozotocin challenged + 0.3 g/kg BW metformin
- Group 4, FFP0.1 diabetic (n=5): HFD + streptozotocin challenged + 0.1 g/kg BW of FFP
- Group 5, FFP1.0 diabetic (n=5): HFD + streptozotocin challenged + 1.0 g/kg BW of FFP

During the experimental period, fasting blood glucose level and food intake were measured weekly. Calorie intake per mouse was calculated based on the calorie/g for the standard diet and HFD (Table 2). At the end of the 18 weeks of experimental period, all mice were anesthetized with isoflurane (Sigma-Aldrich Co.) and euthanized by cervical dislocation. Liver, gonadal fat pads, and serum were collected and subjected to the following assays.

**Oral glucose tolerance test (OGTT)**

On week 17, all mice that fasted overnight were orally fed with 2.5 g/kg BW of glucose (Sigma-Aldrich Co.). Subsequently, blood glucose level of the mice collected from tail vein was measured at 30, 60, 90, 120, and 180 minutes using OneTouch glucose meter (LifeScan, Inc, Chesterbrook, PA, USA).

**Insulin tolerance test (ITT)**

One week before the end of the experiment, all mice that fasted 6 hours were injected with 1 IU/kg BW of insulin intraperitoneal injection (CCM Pharmaceuticals Sdn Bhd). Subsequently, blood glucose level of the mice was measured for 30, 60, 90, 120, and 180 minutes using OneTouch glucose meter.

**Serum liver markers, insulin, and leptin**

Serum was collected for quantification of the following enzyme markers (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], and creatinine) and lipid profile (total cholesterol and triglyceride [TG]). The assays were performed in a biochemical analyzer (Hitachi 902 Automatic Analyzer; Hitachi Ltd., Tokyo, Japan) with adapted reagents from Hoffman-La Roche Ltd. (Basel, Switzerland). In addition, insulin and leptin levels in the serum were also determined using insulin and leptin ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).

**Differential gene expression using real-time quantitative PCR (RT-qPCR)**

Expressions of inducible nitric oxide synthase (iNOS), nuclear factor kappa light chain enhancer of activated B cells (NF-κB), carnitine palmitoyl transferase I (CPT1a), glucokinase, glucose-6-phosphate dehydrogenase (G6PD), phosphofructokinase and 6-phosphogluconate dehydrogenase in

---

**Table 2** Major components of the standard diet and high-fat diet

<table>
<thead>
<tr>
<th>Content</th>
<th>Standard pellet (g%) (Gold Coin, Malaysia)</th>
<th>D12492 (g%) (Research Diet, USA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein</td>
<td>22.0</td>
<td>26.2</td>
</tr>
<tr>
<td>Fiber</td>
<td>5.0</td>
<td>6.0</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>49.0</td>
<td>26.3</td>
</tr>
<tr>
<td>Fat</td>
<td>3.0</td>
<td>34.9</td>
</tr>
<tr>
<td>Others</td>
<td>21.0</td>
<td>6.6</td>
</tr>
<tr>
<td>Total kcal</td>
<td>38.3</td>
<td>51.2</td>
</tr>
</tbody>
</table>

RT-qPCR was performed with NEX proq PCR Evagreen Master Mix (NEX Diagnostics) using Eco Real Time PCR system (Illumina, San Diego, CA, USA) with the following steps: 95°C for 2 minutes, 40 cycles of 95°C for 10 seconds, 60°C for 45 seconds, and acquisition of fluorescent signal. Specificity and efficiency of primers were confirmed by RT-qPCR melt curve and standard curve analysis. Non-template controls were used to confirm specificity. All samples were measured in triplicate. The expression levels of the target genes in all samples were normalized using the three housekeeping genes and further compared with those in the untreated control group by the Eco 48 software (Illumina). All the results were expressed as normalized fold changes compared with the untreated diabetic group.

**Glycogen and nitric oxide (NO) quantification**

Liver was excised from each mouse, washed with ice-cold phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM NaHPO₄, 2 mM K₂HPO₄, pH 7.4; Sigma-Aldrich Co.), and weighted. One part of the liver was mashed using a 0.2 μm cell strainer and syringe rubber plunger in cold PBS, to obtain a liver homogenate. The liver homogenate was used to determine the levels of glycogen and NO by using ELISA kit (Sigma-Aldrich Co.) and Griess assay (Thermo Fisher Scientific), respectively.

**Serum adipokine quantification**

Serum collected for the biomarkers evaluation was also subjected to interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) quantification using ELISA kits (R&D Systems).

**Statistical analysis**

Mean and standard deviation from five mice per group were calculated by using Excel. Significant difference ($p<0.05$) between the untreated diabetic mice with other groups for all experiments was tested using one-way analysis of variance followed by post hoc Duncan analysis using SPSS version 20 (IBM Corporation, Armonk, NY, USA).

**Results**

After 12 weeks of incubation, HFD streptozotocin-challenged diabetic mice were observed with three times higher fasting blood glucose compared with normal healthy mice ($p<0.05$). For the following 6 weeks, untreated diabetic mice were recorded with further increase of fasting glucose to ~300 mg/dL while normal healthy mice maintained the fasting blood glucose below 100 mg/dL ($p<0.05$). Metformin-treated mice maintained lower fasting blood glucose than the
untreated diabetic mice throughout the 6-week study period ($p<0.05$). Moreover, FFP diet-supplemented mice also had reduced fasting blood glucose compared with untreated diabetic mice. After 3 weeks of FFP supplementation, FFP1.0 showed better effect than FFP0.1 in reducing the fasting blood glucose ($p<0.05$) (Figure 1A).

**ITT and OGTT**

ITTs (Figure 1B) and OGTT (Figure 1C) were performed to measure insulin sensitivity and glucose tolerance. Compared with the untreated diabetic mice that had impaired glucose tolerance, metformin-treated and FFP diet-supplemented mice were observed with improved glucose metabolism and insulin sensitivity in the OGTT and ITT. When the two evaluated concentrations of FFP were compared, FFP1.0 was observed with faster reduction of glucose level and was able to maintain low blood glucose level even after 2.5 hours of insulin injection than in FFP0.1 supplemented mice.

**Food and calorie intake per mouse**

Overall, diabetic mice were recorded with significantly ($p<0.05$) higher food/calorie intake than normal healthy mice (Figure 2A and B). Within the first 5 weeks of treatment, no significant difference was observed for food/calorie intake among all groups of diabetic mice. On the other hand, significantly lower level of food/calorie intake was observed in diabetic mice treated with metformin or supplemented with FFP1.0 after 6 weeks of duration. (Figure 2A and B).

**Serum insulin and leptin levels**

The effect of FFP, particularly at 1 g/kg BW, in sensitizing the insulin was further supported with the reduction of fasting serum insulin and serum leptin levels (Table 4). Untreated diabetic mice were recorded with higher levels of serum insulin and serum leptin. On the other hand, metformin treatment and FFP1.0 diet supplementation significantly ($p<0.05$) reduced the serum insulin and serum leptin levels compared with the untreated mice. FFP0.1 only significantly reduced the serum insulin level compared with the untreated mice.

**Serum lipid and liver enzyme profiles**

Untreated diabetic mice were recorded with higher levels of serum lipid (cholesterol and TG) and liver enzyme (AST,
ALP, and AST) profiles. Metformin-treated diabetic mice were also recorded with significant (p<0.05) lower level of serum lipid and liver enzyme profiles compared with untreated mice (Table 5). FFP0.1 diet-supplemented mice were recorded with significantly (p<0.05) lower level of only serum TG, ALT, and ALP levels. In addition, FFP1.0 was also observed with significantly (p<0.05) lower level of serum lipid and liver enzyme profiles compared with the untreated diabetic mice. Ten times higher supplementation of FFP on diabetic mice significantly (p<0.05) further reduced the serum cholesterol, TG, ALP, and AST levels (Table 5).

Liver glycogen level
Untreated diabetic mice were recorded with 4.5-fold lower liver glycogen level compared to the normal healthy mice. Metformin, FFP1.0, and FFP0.1 were able to increase liver glycogen level by 3.00-, 2.15-, and 3.57-fold, respectively, compared with the untreated diabetic mice after 6 weeks of duration (Figure 3).

Table 4 Serum insulin and leptin, of normal, untreated diabetic, metformin-treated diabetic and fermented food paste-supplemented diabetic mice after 6 weeks of duration

<table>
<thead>
<tr>
<th>Grouping</th>
<th>Serum insulin (ng/mL)</th>
<th>Serum leptin (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>1.68±0.12&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.29±0.21&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Untreated</td>
<td>2.97±0.11&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.36±0.25&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Metformin</td>
<td>1.89±0.09&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5.77±0.31&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>FFP0.1</td>
<td>2.34±0.10&lt;sup&gt;d&lt;/sup&gt;</td>
<td>7.14±0.25&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>FFP1.0</td>
<td>1.82±0.13&lt;sup&gt;e&lt;/sup&gt;</td>
<td>5.21±0.27&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Note: Different superscript letters indicate a significant difference compared with the untreated diabetic group, p<0.05.

Expression of glucose metabolism, insulin signaling, and adipogenesis-related genes
To understand how FFP regulates the glucose metabolism and insulin signaling pathway in the diabetic mice, expression of several genes that related to these pathways was observed by RT-qPCR. In the liver tissue, the expression of G6PD, glucokinase, phosphofructokinase, and 6-phosphogluconate dehydrogenase genes was found to be increased in the liver tissue of metformin-treated and FFP1.0 diet-supplemented diabetic mice (Figure 4). Moreover, expression of insulin signaling pathway-related genes, that is, Glut1, Glut4, Glut8, adiponectin, and insulin receptor genes were also ameliorated by the metformin treatment and FFP1.0 diet supplementation in the fat pad of the diabetic mice (Figure 5). In terms of adipogenesis-related genes, metformin treatment and FFP1.0 diet supplementation were able to ameliorate the expression of CPT1a gene in liver (Figure 4) while the expression of SREBP1 gene in the fat pad was suppressed (Figure 6). When FFP1.0 and FFP0.1 diet supplementations were compared, 10 times higher dosage of FFP showed significantly (p<0.05) additional benefit in ameliorating the expression of these evaluated genes in liver and fat pad.

Serum IL-1β and TNF-α adipokine levels
Untreated diabetic mice were observed with highest serum IL-1β and TNF-α levels. On the other hand, metformin, FFP1.0, and FFP0.1 similarly helped to reduce the levels of IL-1β and TNF-α proinflammatory adipokines compared with the untreated diabetic mice. Both metformin treatment and FFP supplementation have even helped to reduce the level of serum IL-1β near to the level of normal healthy mice (Figure 5).
Gene expression of NF-kB and iNOS in the liver
FFP1.0 diet supplementation showed the highest suppression on the expression of proinflammatory related genes iNOS and NF-kB in the liver compared with the untreated diabetic mice. On the other hand, metformin treatment and FFP0.1 diet supplementation showed lower degree (but significant, \( p<0.05 \)) of iNOS and NF-kB expression in the liver compared with the diabetic mice (Figure 7A).

NO level in the liver
Untreated diabetic mice were recorded with 2.9-fold higher liver NO level compared with the normal healthy mice. Metformin and FFP1.0 were able to reduce \( ~55\% \) of the liver NO level in the diabetic mice after 6 weeks of duration. On the other hand, FFP0.1 reduced only \( 13\% \) of the liver NO level compared with the diabetic mice (Figure 7B).

Discussion
Fermented food including FFP has been widely consumed as health supplements. However, health benefits of different types of fermented food can be varied contributed by the different source of food and strains of microbes used for the fermentation. Thus, it is important to evaluate the efficacy of fermented food to correlate with its health claim. In this study, the antihyperglycemic and anti-inflammatory effects of FFP were evaluated on the HFD + streptozotocin challenged diabetic mice. Previous study has shown that HFD-fed mice with streptozotocin impaired glucose tolerance as a result of the loss of early phase insulin secretion and subsequently caused insulin resistance. In this study, mice fed with HFD and single dose of streptozotocin were found to develop hyperglycemia after 12 weeks of observation. In this study, the untreated diabetic mice were observed with pathological condition of type 2 diabetes such as hyperglycemia, insulin resistant, depletion of liver glycogen, deposition of fat, and secretion of various adipokines such as TNF-\( \alpha \) and leptin.

Like metformin, FFP possessed antihyperglycemic effect after 6 weeks of diet supplementation. Reduction of blood glucose level by FFP was contributed by improved insulin sensitivity and glucose metabolism, which were indicated by the OGTT and ITT. Improved oral glucose tolerance value indicates enhanced adipose and liver sensitivity to insulin. Improvement of insulin resistance by FFP was supported by the upregulation of three different glucose transporters (Glut1, Glut4, and Glut8) and insulin receptor in the adipose tissue. Upregulation of glucose transporter gene expression also gives the clue that insulin sensitization by FFP diet supplement may achieve through increasing the translocation and glucose uptake in the diabetic mice. FFP diet supplement was also observed to have higher level of liver glycogen. Glycogen is the primary intracellular storable form of glucose converted by insulin in liver via activation of glycogen synthesis. Thus, enhancement of glycogen synthesis in the liver was also observed, indicating the improvement of hepatic insulin sensitivity in the type 2 diabetes. Furthermore, insulin was also involved in the activation of liver metabolism.

Table 5 Serum lipid (cholesterol and TG) and liver enzymes (ALT, ALP, and AST) profiles of normal, untreated diabetic, metformin-treated diabetic and FFP-supplemented diabetic mice after 6 weeks of duration

<table>
<thead>
<tr>
<th></th>
<th>Cholesterol (mmol/L)</th>
<th>TG (mmol/L)</th>
<th>ALT (U/L)</th>
<th>ALP (U/L)</th>
<th>AST (U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>2.52±0.08(^a)</td>
<td>1.35±0.06(^a)</td>
<td>69.30±8.68(^a)</td>
<td>49.33±1.41(^a)</td>
<td>167.66±18.92(^a)</td>
</tr>
<tr>
<td>Untreated</td>
<td>5.28±0.74(^b)</td>
<td>4.83±0.02(^b)</td>
<td>175.30±7.78(^b)</td>
<td>126.67±8.18(^b)</td>
<td>337.18±18.80(^b)</td>
</tr>
<tr>
<td>Metformin</td>
<td>4.59±0.03(^c)</td>
<td>2.76±0.04(^c)</td>
<td>81.25±4.95(^c)</td>
<td>88.00±4.14(^c)</td>
<td>253.76±15.22(^c)</td>
</tr>
<tr>
<td>FFP0.1</td>
<td>5.74±0.32(^d)</td>
<td>1.92±0.01(^d)</td>
<td>73.25±5.44(^d)</td>
<td>73.33±3.94(^d)</td>
<td>299.76±17.57(^d)</td>
</tr>
<tr>
<td>FFP1.0</td>
<td>4.77±0.29(^e)</td>
<td>1.20±0.06(^e)</td>
<td>70.35±3.80(^e)</td>
<td>56.00±5.66(^e)</td>
<td>213.50±14.00(^e)</td>
</tr>
</tbody>
</table>

Notes: Different superscript letters indicate a significant difference compared with the untreated diabetic group, \( p<0.05 \). FFP0.1 and FFP1.0 indicate 0.1 and 1.0 g, respectively, of FFP per kg of body weight.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FFP, fermented food paste; TG, triglyceride.
through ameliorating the expression of genes related to glycolysis such as glucokinase, G6PD, phosphofructokinase, and 6-phosphogluconate dehydrogenase, which was also observed in the FFP diet-supplemented diabetic mice.

Adipokines are proteins secreted by adipocytes that are known to have direct or indirect regulation on insulin sensitivity. In this study, dysregulation on the production of adipokines such as leptin, adiponectin, IL-1β, and TNF-α was observed in the untreated diabetic mice. Leptin, stimulated by hyperinsulinemia, is a hormone produced by adipocytes that promotes body fat accumulation. Over accumulation of leptin always promotes excessive food intake and reduces energy expenditure in obese subjects. On the other hand, adiponectin is a hormone produced by adipocytes that positively regulates energy expenditure and suppresses excessive food intake. IL-1β and TNF-α are proinflammatory cytokines that inhibit insulin secretion and induce apoptosis of β-cells via stimulating the generation of NO through the activation of inflammation. In this study, FFP diet supplement was able to upregulate the expression of adiponectin associated with reduced level of serum leptin, IL-1β, and TNF-α. In addition, reduced level of proinflammatory IL-1β was observed

![Figure 4](image1.png)

**Figure 4** Differential expression of G6PD, glucokinase, phosphofructokinase, 6-phosphogluconate dehydrogenase, and CPT1a hepatic genes on normal, untreated, metformin-treated, and FFP-supplemented diabetic mice. The expression of target genes (± SEM) was normalized with β-actin, and the untreated diabetic group was used as control for comparison. Fold change >2 compared with the untreated group was considered significant. Different superscript letters indicate a significant difference compared with the untreated diabetic group, *p* < 0.05.

**Note:** FFP0.1 and FFP1.0 indicate 0.1 and 1.0 g, respectively, of FFP per kg of body weight.

**Abbreviation:** FFP, fermented food paste.

![Figure 5](image2.png)

**Figure 5** Serum (A) IL-1β and (B) TNF-α of normal, untreated, metformin-treated, and FFP-supplemented diabetic mice. Different superscript letters indicate a significant difference compared with the untreated diabetic group, *p* < 0.05.

**Note:** FFP0.1 and FFP1.0 indicate 0.1 and 1.0 g, respectively, of FFP per kg of body weight.

**Abbreviations:** IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; FFP, fermented food paste.
with the suppression of liver inflammation indicated by the lower level of liver NO and downregulation of expression of inflammatory markers NF-kB and iNOS. Reduced level of liver inflammation may contribute to the recovery of mild liver damage shown by lower level of serum liver enzyme profile in the FFP-supplemented diabetic mice. Moreover, suppression of leptin and improved insulin sensitivity may help to control the appetite of the diabetic mice as previous study has reported that leptin combined with insulin has reduced food intake and BW of rat. In addition, promotion of adiponectin expression and improvement of insulin sensitivity by FFP may also helped to reduce fat accumulation as indicated by lower levels of serum cholesterol and TG in the FFP-supplemented mice, which was similar to the previous reports that evaluated the role of adipokines.22,24 Besides improved insulin resistance, 6 weeks of FFP diet supplement was able to ameliorate the expression of CPT1a gene in liver, which was involved in fatty acid oxidation.23 On the contrary, it suppressed the expression of SREBP1 gene, which plays an important role in mediating accumulation of lipid and cholesterol homeostasis.24 Thus, improvement of serum cholesterol and TG level by FFP may also be contributed by the activation of lipid metabolism.

Foods including vegetables, mushrooms, fruits, herbs, and seaweed, which were used to produce FFP are known as natural sources of antioxidants, vitamins, and minerals.26

Figure 6 Differential expressions of Glut1, Glut4, Glut8, adiponectin, insulin receptor, and SREBP1 genes in the fat pad of normal, untreated, metformin-treated, and FFP-supplemented diabetic mice. The expression of target genes (±SEM) was normalized with β-actin and the untreated diabetic group was used as control for comparison. Fold change ≥2 when compared with the untreated group was considered significant. Different superscript letters indicate a significant difference compared with the untreated diabetic group, p<0.05.

Note: FFP0.1 and FFP1.0 indicate 0.1 and 1.0 g, respectively, of FFP per kg of body weight.

Abbreviation: FFP, fermented food paste.

Figure 7 (A) Differential expression of NF-kB and iNOS genes in the liver of normal, untreated, metformin-treated, and FFP-supplemented diabetic mice. The expression of target genes (±SEM) was normalized with β-actin, and the untreated diabetic group was used as control for comparison. Fold change ≥2 when compared with the untreated group was considered significant. (B) NO levels in liver of normal, untreated, metformin-treated, and FFP-supplemented diabetic mice. Different superscript letters indicate a significant difference compared with the untreated diabetic group, p<0.05.

Note: FFP0.1 and FFP1.0 indicate 0.1 and 1.0 g, respectively, of FFP per kg of body weight.

Abbreviations: NO, nitric oxide; FFP, fermented food paste; iNOS, inducible nitric oxide synthase; NF-kB, nuclear factor kappa B.
Furthermore, fermentation by lactic acid bacteria was proposed as a biological process that can enhance the biological activities of natural food. Previous study has reported that FFP contained oligosaccharides, essential amino acids, vitamins, and polyphenolic acids. A pilot clinical trial has shown that supplementation with amino acid helped to reduce the plasma glucose and improved insulin sensitivity of type 2 diabetes patients. Moreover, amino acid arginine was also found to improve glucose tolerance in obese mice. On the other hand, polyphenolic acids particularly caffeoylquinic acid, which is the most abundant polyphenol in FFP, were reported with antihyperglycemic and anti-inflammatory effects. Oligosaccharides in various types of food including mushrooms were also reported with antiabetic effect. Thus, the antihyperglycemic and anti-inflammatory effects of FFP may be contributed by not only the polyphenolic acids but also essential amino acids, oligosaccharides, and even other bioactive metabolites that are present in the sample.

It can be concluded that FFP possessed antihyperglycemic and anti-inflammatory effects toward the HFD-streptozotocin-challenged mice. This antidiabetic effect was mainly contributed by improved insulin sensitivity, glucose metabolism, glycosen metabolism, and inhibition of lipid deposition. The observed activities can be contributed by the presence of essential amino acids, vitamins, and polyphenolic acids in the FFP as reported in the previous study.

**Acknowledgment**

Dr Kamariah Long would like to thank Elken Global Sdn Bhd for awarding the research grant.

**Author contributions**

All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**

Noraisyah Zulkawi and Kam Heng Ng are from Elken Global Sdn. Bhd, Malaysia, which funded this study. The authors report no other conflicts of interest in this work.

**References**


